These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1567171)

  • 1. Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer.
    Fountzilas G; Afthonidis D; Geleris P; Salem N; Kottas G; Halkidis C; Apostolidis P; Beer M; Tourkantonis A
    Anticancer Res; 1992; 12(1):231-4. PubMed ID: 1567171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
    Kumpulainen EJ; Hirvikoski PP; Johansson RT
    Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
    Büyükünal E; Derman U; Serdengecti S; Berkarda B
    Chemioterapia; 1987 Oct; 6(5):377-9. PubMed ID: 3322590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
    J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvant combined radiochemotherapy: a feasibility study of a new strategy in stages I and II].
    Serin D; Aimard L; Kirscher S; Brewer Y; Félix-Faure C; Vincent P; Chauvet B; Reboul F
    Bull Cancer; 1997 Mar; 84(3):247-53. PubMed ID: 9207869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
    J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
    Chemioterapia; 1988 Oct; 7(5):345-9. PubMed ID: 3224403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
    Martin M; Lluch A; Ojeda B; Barnabas A; Colomer R; Massuti B; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-26-S17-30. PubMed ID: 9374088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
    Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
    Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.